Clinical Practice Session
Controversies in C3 Glomerulopathy
November 03, 2023 | 04:30 PM - 06:00 PM
Location: Room 201, Pennsylvania Convention Center
Session Description
This session highlights a number of the controversies related to the underlying pathomechanisms, associated biomarkers, and clinical presentation of C3 glomerulopathy (C3G). It concludes with a summary of current management and consideration for initiating targeted therapeutics.
ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Hans Anders.
Session support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Summarize the natural history and clinical confounders of diagnosis of C3G, including PIGN, MGRS, ICGN, and nonspecific complement deposition on kidney biopsies
- Discuss the application and promise of the peripheral, kidney, and histologic biomarkers of C3G
- Outline the autoimmune proteins, genetic abnormalities, and novel drivers of complement dysregulation in C3G
- Describe the standard of care, compassionate use of targeted therapeutics, and the value of trial enrollment for C3G
Learning Pathway(s)
- Glomerular Diseases
Moderators
Presentations
- What Is C3 Glomerulopathy and What Is It Not?
04:30 PM - 04:50 PM
- Drivers of C3 Glomerulopathy
04:50 PM - 05:10 PM
- Role of Biomarkers in C3 Glomerulopathy
05:10 PM - 05:30 PM
- Standard Immune Suppression and Targeted Therapeutics in C3 Glomerulopathy
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM